The statin wars: why AstraZeneca must retreat

  title={The statin wars: why AstraZeneca must retreat},
  author={The Lancet},
  journal={The Lancet},

Topics from this paper

Is Pharmaceutical Detailing Informative? Evidence from Contraindicated Drug Prescriptions
Strong evidence is found for the informative-advertising hypothesis: the match quality signaled by doctor-level advertising for contraindicated patients is significantly inferior to that signaled for the other patients. Expand
Benefits & risks of statin therapy for primary prevention of cardiovascular disease in Asian Indians – A population with the highest risk of premature coronary artery disease & diabetes
The updated 2013 Cochrane review has put to rest all lingering doubts about the overwhelming benefits of long-term statin therapy in primary prevention by conclusively demonstrating highly significant reductions in all-cause mortality, major adverse cardiovascular events (MACE) and the need for coronary artery revascularization procedures (CARPs). Expand
Data Mining of the Public Version of the FDA Adverse Event Reporting System
The latest information on this area is summarized for future pharmacoepidemiological studies and/or pharmacovigilance analyses. Expand
Beyond established and novel risk factors: lifestyle risk factors for cardiovascular disease.
Although efforts to combat established and novel risk factors with pharmacological treatments are important and should continue, this work calls for a systematic rebalancing of current research, clinical care, and policy efforts to focus more on lifestyle. Expand
Therapeutic traditions, patient socioeconomic characteristics and physicians’ early new drug prescribing–a multilevel analysis of rosuvastatin prescription in south Sweden
Contextual characteristics of the HCP seem to be relevant for understanding physicians’ motivation to adopt rosuvastatin, and inequity in health care as the socioeconomic status of the patients appears to influence the prescribing behavior of the physicians irrespective of medical reasons. Expand
Spiralling Medical Costs: Why Canada Needs NICE Medicine.
  • N. Temple
  • Medicine
  • Healthcare policy = Politiques de sante
  • 2007
Drug costs in Canada could be greatly reduced if doctors prescribed lower-cost alternatives where appropriate (therapeutic substitution) and proposals are made for changes in the regulatory agencies responsible for the approval of drugs, drug marketing and post-marketing surveillance. Expand
Understanding the effects of a decentralized budget on physicians' compliance with guidelines for statin prescription – a multilevel methodological approach
A decentralized drug budget seems to promote adherence to guidelines for statin prescription in Scania, Sweden, but the high practice differences at the end of the observation period may reflect inefficient therapeutic traditions, and indicates that rational statin prescriptions could be further improved. Expand
Cost‐Efficacy Analysis of 3‐Hydroxy‐3‐Methylglutaryl Coenzyme A Reductase Inhibitors Based on Results of the STELLAR Trial: Clinical Implications for Therapeutic Selection
The cost/1% reduction in low‐density lipoprotein cholesterol (LDL) and the cost/patient achieving the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) LDL goal based on the results of the STELLAR trial are compared. Expand
The Safety of Rosuvastatin as Used in Common Clinical Practice: A Postmarketing Analysis
Concerns about the relative safety of rosuvastatin at the range of doses used in common clinical practice in the general population are supported. Expand
Wetenschapsfilosofie en commerciële belangen in het debat over evidence-based geneeskunde
De afgelopen jaren hebben RCT’s ertoe geleid dat enkele pathofysiologische inzichten grondig zijn gewijzigd. Expand